PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. More Details
Solid track record with mediocre balance sheet.
Share Price & News
How has PerkinElmer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PKI has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: PKI underperformed the US Life Sciences industry which returned 47.1% over the past year.
Return vs Market: PKI exceeded the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs PerkinElmer (NYSE:PKI) Using Too Much Debt?
3 weeks ago | Simply Wall StEstimating The Fair Value Of PerkinElmer, Inc. (NYSE:PKI)
1 month ago | Simply Wall StHave Insiders Been Selling PerkinElmer, Inc. (NYSE:PKI) Shares?
Is PerkinElmer undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PKI ($124.45) is trading above our estimate of fair value ($110.3)
Significantly Below Fair Value: PKI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PKI is poor value based on its PE Ratio (47x) compared to the US Life Sciences industry average (43.5x).
PE vs Market: PKI is poor value based on its PE Ratio (47x) compared to the US market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: PKI is poor value based on its PEG Ratio (4.9x)
Price to Book Ratio
PB vs Industry: PKI is good value based on its PB Ratio (4.7x) compared to the US Life Sciences industry average (6.8x).
How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PKI's forecast earnings growth (9.7% per year) is above the savings rate (2.2%).
Earnings vs Market: PKI's earnings (9.7% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: PKI's earnings are forecast to grow, but not significantly.
Revenue vs Market: PKI's revenue (3.6% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: PKI's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (16.7%).
How has PerkinElmer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PKI has high quality earnings.
Growing Profit Margin: PKI's current net profit margins (9.9%) are higher than last year (8.9%).
Past Earnings Growth Analysis
Earnings Trend: PKI's earnings have grown by 6.4% per year over the past 5 years.
Accelerating Growth: PKI's earnings growth over the past year (17.5%) exceeds its 5-year average (6.4% per year).
Earnings vs Industry: PKI earnings growth over the past year (17.5%) exceeded the Life Sciences industry 17%.
Return on Equity
High ROE: PKI's Return on Equity (9.9%) is considered low.
How is PerkinElmer's financial position?
Financial Position Analysis
Short Term Liabilities: PKI's short term assets ($1.5B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: PKI's short term assets ($1.5B) do not cover its long term liabilities ($2.5B).
Debt to Equity History and Analysis
Debt Level: PKI's debt to equity ratio (65.2%) is considered high.
Reducing Debt: PKI's debt to equity ratio has increased from 45.1% to 65.2% over the past 5 years.
Debt Coverage: PKI's debt is well covered by operating cash flow (26.9%).
Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (8.4x coverage).
What is PerkinElmer current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PKI's dividend (0.22%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.63%).
High Dividend: PKI's dividend (0.22%) is low compared to the top 25% of dividend payers in the US market (4.56%).
Stability and Growth of Payments
Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: PKI is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prahlad Singh (55 yo)
Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. He serves as Director of PerkinElmer, Inc. since August 21, 2019. He has been President at Perki ...
CEO Compensation Analysis
Compensation vs Market: Prahlad's total compensation ($USD4.12M) is below average for companies of similar size in the US market ($USD11.16M).
Compensation vs Earnings: Prahlad's compensation has increased by more than 20% in the past year.
|CEO, President & Director||0.83yr||US$4.12m||0.034% |
|Senior VP & CFO||2.42yrs||US$2.11m||0.023% |
|Senior VP of Administration||12.25yrs||US$2.88m||0.063% |
|Senior Vice President of Global Operations||no data||no data||0.0087% |
|VP & Chief Accounting Officer||9.5yrs||no data||0.0092% |
|Vice President of Investor Relations||no data||no data||no data|
|Senior Vice President of Strategy & Business Development||4.75yrs||no data||0.0066% |
|CFO of Human Health & Corporate Treasurer||no data||no data||no data|
|VP, Associate General Counsel & Assistant Secretary||no data||no data||no data|
|Vice President of Technology & Innovation||no data||no data||no data|
Experienced Management: PKI's management team is considered experienced (3.6 years average tenure).
|CEO, President & Director||0.83yr||US$4.12m||0.034% |
|Independent Non-Executive Chairman||0.83yr||US$338.48k||0.057% |
|Independent Director||5.67yrs||US$264.98k||0.013% |
|Independent Director||8.67yrs||US$279.98k||0.019% |
|Independent Director||4.25yrs||US$264.98k||0.0097% |
|Independent Director||4yrs||US$289.98k||0.0091% |
|Independent Director||3yrs||US$264.98k||0.0032% |
|Independent Director||0.58yr||no data||0.0014% |
Experienced Board: PKI's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PerkinElmer, Inc.
- Ticker: PKI
- Exchange: NYSE
- Founded: 1937
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$13.915b
- Shares outstanding: 111.81m
- Website: https://www.perkinelmer.com
Number of Employees
- PerkinElmer, Inc.
- 940 Winter Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PKI||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|PKN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|0KHE||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|PKI *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|P1KI34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solution ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 05:41|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.